Ohio State University James Cancer Center, Columbus, OH
Claire Han , Kerryn Reding , Matthew Kalady , Rachel Lynn Yung , Electra Paskett
Background: Colorectal cancer (CRC) survivors often experience long-term symptom toxicity after cancer treatments. We described persistent gastrointestinal (GI) toxicity related to cancer and treatments in long-term CRC survivors and assessed the risk and life impact factors of GI toxicity. Methods: A cross-sectional study utilized data from the Women’s Health Initiative (WHI) Life and Longevity After Cancer (LILAC) study that recruited postmenopausal women. CRC survivors after cancer treatments were included (N = 413). Pearson correlations/A Chi-square test and multivariable linear regression models were used to identify risk and impact factors of GI toxicity. Results: 81% of CRC survivors experienced persistent GI toxicity. Bloating/gas was the most prevalent (54.2%) and severe, followed by constipation (34.1%), diarrhea (33.4%), and abdominal/pelvic pain (28.6%). Time since cancer diagnosis (< 5 years), advanced cancer stage, low income, high psychological distress, poor dietary habits and physical activity, and impaired life impact measures (health-related quality of life, daily life interferences, and body image) were significantly associated with several GI toxicities. Fatigue and sleep disturbance were the most significantly associated with long-term GI toxicity (Table 1). Abdominal/pelvic pain significantly influenced life impact measures. Conclusions: GI toxicities are highly prevalent among CRC survivors, specifically in patients with high psychological distress. A better understanding of the long-term GI toxicity in CRC survivors and identifying those more vulnerable may inform future directions for managing CRC survivorship. An individualized, multifaceted intervention is warranted to consider psychosocial support, lifestyle intervention, and physical rehabilitation.
Unstandardized β (95% CI) | SE | Standardized β | t, p | |
---|---|---|---|---|
Potential Predictors of GI Toxicity (0 no to 3 severe) | ||||
Bloating/Gas | ||||
Fatigue | 0.22 (0.09, 0.34) | .06 | 0.21 | 3.468, .001 |
Sleep Disturbances | 0.13 (0.02, 0.23) | .05 | 0.14 | 2.242, .026 |
Constipation | ||||
Depression | 0.17 (0.03, 0.31) | .07 | 0.15 | 2.415, .016 |
Diarrhea | ||||
Sleep Disturbances | 0.16 (0.06, 0.25) | .05 | 0.19 | 3.245, .001 |
Dietary Habits | -0.08 (-0.15, -0.01) | .03 | -0.12 | -2.088, .038 |
Fecal Leakage | ||||
Sleep Disturbances | 0.09 (0.01, 0.17) | .04 | 0.14 | 2.233, .026 |
Abdominal/Pelvic Pain | ||||
Fatigue | 0.13 (0.04, 0.22) | .04 | 0.18 | 2.947, .003 |
Sleep Disturbances | 0.12 (0.04, 0.19) | .04 | 0.18 | 2.994, .003 |
Heartburn | ||||
Fatigue | 0.14 (0.05, 0.24) | .04 | 0.18 | 3.026, .003 |
Composite GI Toxicity Score | ||||
Fatigue | 0.65 (0.29, 0.99) | .18 | 0.21 | 3.557, < .001 |
Sleep Disturbances | 0.54 (0.22, 0.84) | .16 | 0.20 | 3.336, .001 |
Linear regression model was adjusted for race, education, marital status, insurance type, BMI, cancer stage, treatment, time since diagnosis, and co-morbidities and income.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Rachel Tillery Webster
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Rebecca Smith
2024 ASCO Breakthrough
First Author: Marco Santos Teles
2023 ASCO Annual Meeting
First Author: Vidhya Nair